Effects of glibenclamide, metformin and insulin on the incidence and latency of death by oubain-induced arrhythmias in mice

Pharmacological Research

Volumn 45, Issue 3, 2002, Pages 183-187

  Yazar, Aziz ^a   Polat, Gürbüz ^a   Ün, Ismail ^a   Levent, Adnan ^a   Kaygusuz, Ayşe ^a   Çamdeviren, Handan ^a   Büyükafşar, Kansu ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Arrhythmia; Glibenclamide; Insulin; Metformin; Oubain

Indexed keywords

CARDIAC GLYCOSIDE; GLIBENCLAMIDE; GLUCOSE; INSULIN; METFORMIN; NEUTRAL INSULIN; OUABAIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCULATION; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; INCIDENCE; LATENT PERIOD; LETHALITY; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL;

EID: 0036444281     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0944     Document Type: Article

References (31)

1. ATP channels in coronary perfused ventricular muscles of guinea-pigs. J Mol Cell Cardiol 1999; 31: 533-42.
2. Lingrel JB. Na, K-ATPase: Isoform structure, function, and expression. J Bioenerg Biomembr 1992; 24: 263-70.
3. Jonkman FAM, Boddeke WGM, van Zwieten PA. Protective activity of calcium entry blockers against ouabin intoxication in anesthetized guinea-pigs. J Cardiovasc Pharmacol 1986; 8: 1009-13.
4. + channel openers. Pharmacol Ther 2000; 85: 39-53.
5. Wirth KJ, Klaus E, Englert HG, Scholkens BA, Linz W. HMR 1883, a cardioselective K(ATP) channel blocker, inhibits ischaemia- and reperfusion-induced ventricular fibrillation in rats. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 295-300.
6. Tosaki A, Engelman DT, Engelman RM, Das DK. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts. J Pharmacol Exp Ther 1995; 275: 1115-23.
7. Pogatsa G. Potassium channels in the cardiovascular system. Diabetes Res Clin Pact 1995; 28 (Suppl.): S91-8.
8. D'Alonzo AJ, Hess TA, Darbenzio RB, Sewter JC. Effects of intracoronary glyburide on cesium-induced arrhythmias in anesthetized dogs. J Cardiovasc Pharmacol 1994; 23: 446-52.
9. Ruiz-Ceretti E, DeLorenzi F, Lafond JS, Chartier D. Insulin and the resting potential of hypoxic substrate-deprived myocardium. Can J Physiol Pharmacol 1988; 66: 202-6.
10. Gubner RS, Kallman H. Treatment of digitalis toxicity by chelation of serum calcium. Am J Med Sci 1957; 136-44.
11. Cook JR, Pollard JW, Cooley JC. Myocardial contractile force in the treatment of oubain intoxication with disodium EDTA, potassium chloride, and magnesium sulfate. J Lab Clin Med 1967; 69: 292-303.
12. Jonkman FAM, Boddeke HWGM, vanZwieten PA. Protective activity of calcium entry blockers against oubain intoxication in anesthetized guinea-pigs. J Cardiovasc Pharmacol 1986; 8: 1009-13.
13. + channel openers. Pharmacol Ther 2000; 85: 39-53.
14. Schotborgh AE, Wilde AAM. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Cardiovas Res 1997; 34: 73-80.
15. Kantor PF, Coetzee WA, Carmeliet EE, Dennis SC, Opie LH. Reduction of ischemic K loss and arrhythmias in rat hearts. Cir Res 1990; 66: 478-85.
16. Bernauer W. Concerning the effect of the K channel blocking agent glibenclamide on ischemic and reperfusion arrhythmias. Eur J Pharmacol 1997; 326: 147-56.
17. Billman GE, Englert HC, Schölkens BA. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part II: Effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs. J Pharmacol Exp Ther 1998; 286: 1465-73.
18. Pogatsa G, Koltai MZs, Balkanyi I, Devai J, Kiss V. Effects of various hypoglycemic sulphonylureas on the cardiotoxicity of glycosides. Eur J Clin Pharmacol 1985; 28: 367-70.
19. Zhang HL, Li YS, Fu SX, Yang XP. Effects of glibenclamide and tolbutamide on ischemia- and oubain-induced arrhythmias and membrane potentials of ventricular myocardium from rat and guinea-pig. Chung Kuo Yao Li Hsueh Pao 1991; 12: 398-402.
20. Lepran I, Baczko I, Varro A, Papp JG. ATP-sensitive potassium channel modulators: Both pinacidil and glibenclamide produce antiarrhythmic activity during acute myocardial infarction in conscious rats. J Pharmacol Exp Ther 1996; 277: 1215-20.
21. Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron Artery Dis 1994; 5: 767-71.
22. Tosaki A, Szerdahelyi P, Engelman RM, Das DK. Potassium channel openers and blockers: Do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? J Pharmacol Exp Ther 1993; 267: 1355-62.
23. Munch-Ellingsen J, Bugge E, Ytrehus K. Blockade of the K ATP-channel by glibenclamide aggravates ischemic injury, and counteracts ischemic preconditioning. Basic Res Cardiol 1996; 91: 382-8.
24. Immamura Y, Tomoike H, Narishige T, Takahashi T, Kayusaya H, Takeshita A. Glibenclamide decreases basal coronary blood flow in anesthetized dogs. Am J Physiol 1992; 263: 399-404.
25. D'Alonzo AJ, Sewter JC, Darbenzio BR, Hess TA. Effects of cromakalim or glibenclamide on arrhythmias and dispersion of refractoriness in chronically infarcted anesthetized dogs. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 222-8.
26. Brooks WW, Verrier RL, Lown B. Extra-adrenergic mechanisms responsible for the effects of glucose-insulin-potassium solution on vulnerability to ventricular fibrillation. Am J Cardiol 1981; 47: 251-7.
27. Ruiz-Ceretti E, DeLorenzi F, Lafond JS, Chartier D. Insulin and the resting potential of hypoxic substrate-deprived myocardium. Can J Physiol Pharmacol 1988; 66: 202-6.
28. Sinha AK, Bhattacharya S, Acharya K, Mazumder S. Stimulation of nitric oxide synthesis and protective role of insulin in acute thrombosis in vivo. Life Sci 1999; 65: 2687-96.
29. Weiss HR, Rodriguez E, Tse J, Scholz PM. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts. Clin Exp Pharmacol 1994; 21: 607-14.
30. ATP channel induces early and delayed cardioprotective effect: Role of nitric oxide. Am J Physiol 1999; 277: H2425-34.
31. Xi L, Kalkreja RC. Pivotal role of nitric oxide in delayed pharmacological preconditioning against myocardial infarction. Toxicology 2000; 155: 37-44.